Regulatory Perspectives on QbD in Clinical Development Programs
Regulatory Perspectives on QbD in Clinical Development Programs Regulatory Perspectives on QbD in Clinical Development Programs Quality by Design (QbD) has emerged as a significant strategy in the development of pharmaceuticals and biologics. This approach emphasizes the importance of pre-identifying potential risks and ensuring robustness throughout the development lifecycle, particularly in the context of registrational…
Read More “Regulatory Perspectives on QbD in Clinical Development Programs” »